Thursday, January 27, 2011

Tablet coatings made from modified carboxymethylcellulose materials

Abstract:

Coated tablets for the delivery of active ingredients to a user are provided. Such tablets include particular molecular weight-modified carboxymethylcellulose (CMC) coating materials either alone or in combination with other types of hydrocolloids, biogums, cellulose ethers, and the like. The utilization of such modified CMC products aids in the production of such coatings through the availability of larger amounts of base materials with lower amounts of water requiring evaporation therefrom. In such a manner, not only may dimensionally stable, non-tacky, salt tolerant, and quick dissolving edible coatings be produced, but the amount of time required for such manufacture is minimal when compared with traditional methods of production with -based materials. Furthermore, such novel edible non-digestible tablet coatings exhibit delayed dissolution beyond a user's oral cavity for tastemasking purposes, as well as protection of the tablet from environmental conditions and low tackiness properties to prevent adhesion to the user's palate. The novel method of tablet coating manufacture as well as the ultimate coated tablets exhibiting such physical characteristics are also encompassed within this invention.

Claims:

1. A substrate selected from a tablet, a bead, and a microsphere, said substrate coated with a composition comprising modified CMC materials exhibiting a molecular weight range of from 1500 to 75000 and a degree of substitution of less than about 1.5; wherein said composition optionally comprises at least one polymeric additive other than said modified CMC materials.

2. A method of producing such a tablet coating comprising the steps of a) providing a CMC material exhibiting a molecular weight range of from 80000 to 3000000 and degree of substitution of less than about 1.5; b) degrading said CMC materials by exposing said materials to an enzyme in an amount and for a period of time sufficient to reduce the molecular weight range of said CMC materials to a range of from 1500 to 75000; c) inactivating said enzyme; d) producing a solution of the resultant modified CMC materials of step "b" with at most 70% by weight of water and optionally including at most 12.5% of a plasticizer; e) providing a solid tablet formulation; and f) applying said resultant modified CMC materials of step "d" to the at least a portion of the surface of said tablet formulation of step "e", thereby allowing said water therein to evaporate therefrom.

Description:

FIELD OF THE INVENTION

[0001]This invention relates to coated tablets for the delivery of active ingredients to a user. Such tablets include particular molecular weight-modified carboxymethylcellulose (CMC) coating materials either alone or in combination with other types of hydrocolloids, biogums, cellulose ethers, and the like. The utilization of such modified CMC products aids in the production of such coatings through the availability of larger amounts of solids with lower amounts of water requiring evaporation therefrom. In such a manner, not only may dimensionally stable, non-tacky, salt tolerant, and quick dissolving edible coatings be produced, but the amount of time required for such manufacture is minimal when compared with traditional methods of production with cellulose -based materials. Furthermore, such novel edible non-digestible tablet coatings exhibit increased strength, delayed dissolution beyond a user's oral cavity for tastemasking purposes, as well as protection of the tablet from environmental conditions and low tackiness properties to prevent adhesion to the user's palate. The novel method of tablet coating manufacture as well as the ultimate coated tablets exhibiting such physical characteristics are also encompassed within this invention.

BACKGROUND OF THE INVENTION

[0002]Coated tablets exhibit the ability to prevent tasting of the tablet filler and/or active until it passes through the user's oral cavity. Additionally, in order to permit ease in swallowing, such coatings prevent adhesion of the tablet to inner mouth surfaces. Also, aesthetic properties, in terms of clear coatings, printed coatings, and low friability tablets, are also possible through the utilization of such coatings. Furthermore, such a coating provides a layer of protection for the active component therein from environmental exposure as well as from crushing during storage and manufacture, as well as increased strength of tablets. Lastly, such a coating provide a longer duration of pharmacological response after the administration of the dosage form than is ordinarily experienced after the administration of an immediate release dosage form. Such extended periods of response provides for many inherent therapeutic benefits that are not achieved with short acting, immediate release products. In essence, the stability of a pharmaceutical dosage form is related to maintaining its physical, chemical, microbiological, therapeutic, pharmaceutical, and toxicological properties when stored, i.e., in a particular container and environment.

[0003]Hydrophobic polymers such as certain alkyl cellulose derivatives, zein, acrylic resins, waxes, higher aliphatic alcohols, and polylactic and polyglycolic acids have been used in the prior art to develop tablet coatings. Methods of using these polymers to develop coated tablets involve coating the individual dosage units with these hydrophobic polymers. It is known in the prior art that these hydrophobic coatings can be applied either from a solution or suspension. Since most of these polymers have a low solubility in water, they are usually applied by dissolving the polymer in an organic solvent and spraying the solution onto the individual drug forms (such as beads or tablets) and evaporating off the solvent.

[0004]Aqueous dispersions of hydrophobic polymers have been used in the prior art to coat pharmaceutical tablet forms for aesthetic reasons. However, these dosage forms are used for immediate release administration of the active drug contained in the dosage form.

[0005]The ingredients used in such tablet coating formulations often present special problems with regard to their physical stability during storage. For example, waxes which have been used in such formulations are known to undergo physical alterations on prolonged standing, thus precautions are taken to stabilize them at the time of manufacture or to prevent the change from occurring. Fats and waxy materials when used in purified states are known to crystallize in unstable forms, causing unpredictable variations in availability rates during stability testing at the time of manufacture and during later storage. Sugars have also been used for coating purposes and can provide taste improvements. However, such components are also undesirable for tackiness problems and caloric intake increases, not to mention certain complexity problems as well.

[0006]It is known that certain strategies can be undertaken to obtain stabilized pharmaceutical active formulations in many cases, such as insuring that the individual ingredients are in a stable form before they are incorporated into the product, and that processing does not change this condition, delaying the instability by including additional additives, and inducing the individual ingredients of the dosage form to reach a stable state before the product is finally completed. This adds complexity and cost to tablet production methods, however.

[0007]It is also recognized that the moisture content of the pharmaceutical active and filler components can also influence the stability of the tablet. Changes in the porosity and/or hydration level of a polymeric film, such as the ethyl celluloses, can alter the rate of water permeation and drug availability from within a coated tablet. Also, binders such as acacia are known to become less soluble when exposed to moisture and heat. Such problems have been handled by controls in the processing method and proper packaging of the product. Again, however, these methods are quite complex and ultimately expensive to follow.

[0008]Furthermore, the use of organic solvents in the preparation of polymer tablet coatings is considered problematic as the formulations have inherent problems with regard to flammability, carcinogenicity, and safety in general. In addition, the use of organic solvents is disfavored due to environmental concerns.

[0009]Therefore, it is desirable to prepare a coated tablet prepared from an aqueous solution of a hydrophilic polymer that does not require organic solvent or water in relatively large amounts, thereby permitting ease in evaporation while still yielding an effective, protective, non-tacky, additive-compatible coating applied thereto. However, to date, attempts to prepare such coated tablets using aqueous solutions of hydrophilic polymers have been unsuccessful due to stability problems and such excess drying and/or evaporation times required therefore.

ADVANTAGES AND SUMMARY OF THE INVENTION

[0010]It is therefore an advantage of the present invention to provide a new coating for tablet formulations that does not require excessive drying times or high-energy output drying methods to effectively apply such coating to a tablet surface. Another advantage of this invention is the ability of such a coated tablet to perform at the same level of effectiveness of other coated tablets in various manners.

[0011]The present invention encompasses a tablet coated with a composition comprising modified CMC materials exhibiting a molecular weight range of from 1500 to 75000 and a degree of substitution of less than about 1.5; wherein said composition optionally comprises one polymeric additive other than said modified CMC materials. Also encompassed is a method of producing such a tablet coating comprising the steps of a) providing a CMC material exhibiting a molecular weight range of from 80000 to 3000000 and degree of substitution of less than about 1.5; b) degrading said CMC materials by exposing said materials to an enzyme in an amount and for a period of time sufficient to reduce the molecular weight range of said CMC materials to a range of from 1500 to 75000; c) inactivating said enzyme; d) producing a solution of the resultant modified CMC materials of step "b" with at most 90% by weight of water and optionally including at most 12.5% of a plasticizer; e) providing a solid tablet formulation; and f) applying said resultant modified CMC materials of step "d" to the at least a portion of the surface of said tablet formulation of step "e", thereby allowing said water therein to evaporate therefrom. Such tablet coatings thus exhibit at least the same film strength, delayed dissolution, and active protection capabilities as previously made tablet coatings, but with lower manufacturing costs, and potentially reduced stickiness to the palate, increased ease in swallowing as those currently utilized within the pertinent markets. Such an improvement has been realized through the utilization of a single modified CMC component, thereby permitting a reduction in manufacturing complexity of films. Such is a significant benefit over the comparative prior coating compositions that have relied upon combinations of ingredient polymers to provide similarly effective tablet coatings. Although a single modified CMC polymer may be utilized for this application, it is noted that combinations of the required modified CMC polymer with other polymeric additives, such as hydrocolloids, biogums, sugars, and cellulose ethers may be practiced as well. Such a tablet coating of the modified CMC alone or in combination with such other optional gel-forming or non-gelling viscosity building additives is thus highly desired from a cost perspective as well as effectively delayed dissolution when exposed to the moist environment within a user's oral cavity. Such a specific characteristic is advantageous since quickly dissolved coatings may impart undesirable taste of the tablet formulation (including an active, and fillers, such as various types of salts) to the user.

DETAILED DESCRIPTION OF THE INVENTION

[0012]The aqueous solutions of hydrophilic polymers used as coatings in the present invention may be used in conjunction with tablets, spheroids (or beads), microspheres, seeds, pellets, ion-exchange resin beads, and other multi-particulate systems in order to obtain a desired controlled release of the therapeutically active agent.

[0013]The coating formulations of the present invention should be capable of producing a strong, continuous film that is smooth and elegant, capable of supporting pigments and other coating additives, non-toxic, inert, and tack-free.

[0014]Such edible coatings are generally comprised of non-toxic ingredients that permit such desirable properties and can easily be applied to tablets of different shapes and sizes. Gelatin has traditionally been the material of choice within the tablet coating (as well as orally ingested capsule) industry. Gelatin exhibits a number of properties that make such a material a proper candidate for tablet coating including good film forming properties (strength and flexibility, primarily), good solubility in biological fluids at typical body temperature, low viscosity at 50° C. at high solids concentrations, and a gel state at low temperatures. Likewise, ethylcellulose and methylhydroxypropyl cellulose have recently found favor within the tablet industry for the same basic reasons.

[0015]Other typical coatings comprise polymers and films such as pullulan, cellulosics (such as hydroxypropyl cellulose and carboxymethyl cellulose) and sugars, carrageenan, pectin, as well as mixtures of certain low molecular weight varieties of products and high molecular weight types. Although such coatings have been produced in large-scale methods over the last few years, there are certain limitations that are either aesthetically questionable to the consumer or include increased manufacturing costs that are passed on from the tablet manufacturer to the consumer ultimately.

[0016]As noted above, such previously used polymers exhibit certain drawbacks, unfortunately, and particularly in terms of costs of manufacture and application to target tablets. As noted above, high clarity and low tackiness are generally properties sought after by the consumer. Clear, transparent films give an appearance of uniformity and order, whereas the utilization of a tacky film will most likely result in a film that will dissolve only after sticking to the user's palate for an extended period of time. Furthermore, the modified CMC coatings provide limited weight increase during substrate coating steps [normally between about 0.5 and 8% of the total weight of the target substrate (tablet, beads, microspheroids, etc.), preferably from 1 to 4% weight increase, most preferably from 1.5 to about 3.5%), thereby providing an effective protective barrier to the target substrate as well as a strong, yet lightweight one. The modified CMC materials thus exhibit excellent strength, ease in application (from an aqueous source, primarily, though not necessarily), low friability (if any), and sufficient barrier from exposure to undesirable environmental contaminants, all with a very lightweight addition to a target substrate.

[0017]The costs of manufacture have proven difficult to reduce for such previous films, particularly when the amount of film-forming component is relatively low. Solutions of, for instance, hydroxypropylmethyl cellulose (HPMC) including an excess of about 90% or higher by weight of water are typical for such coating materials. Once the solution (syrup) is formed and then applied to a target tablet surface at a substantially uniform thickness, the time required to effectively form the desired film is dependent upon the humidity and temperature of the environment as well as the amount of water required to be evaporated. At such a high level of water, the needed evaporation time is excessive or the amount of heat needed to effectuate such evaporation quickly increases the manufacturing costs to a rather high level. A decrease in water content within the initial solution, although, it may reduce evaporation time ultimately, leads to other problems, most notably the necessity for sufficient mixing to thoroughly disperse such cellulosic materials throughout the solution for proper uniform film production. As such, with too little water present, which results in a too high viscosity, the amount of time and effort required for such needed thorough mixing is inordinately high. In either situation, the cost of manufacture is impacted by the amount of water needed and the ultimate cost for such coating production is ultimately passed on to the consumer.

[0018]For the purpose of this invention, the term "coating" is intended to encompass a solid sheet of polymer material that has been applied in a dimensionally stable manner to at least a portion of a target solid form (such as a tablet, a bead, a microsphere, and the like).

[0019]Polysaccharides, such as certain cellulosic-based types (carboxymethylcellulose, as one non-limiting example), have been utilized within numerous fields for many years as viscosity modifiers, carriers, anti-redeposition agents, and other like purposes within the paper, oil, food, paint, and detergent industries, to name a few. The benefits of modified cellulosics water-soluble polymers have been provided as well, particularly within U.S. Pat. No. 5,569,483 to Timonen et al., as it pertains to substitution of fat within foodstuffs, and within U.S. Pat. No. and 5,543,162 to Timonen et al., as it pertains to the utilization of such enzymatically modified cellulosics in combination with hydrophilic polymers (such as gelatin) in coacervation methods of forming capsules. There is no discussion within either of these references of the ability of specific modified CMC materials for the purpose of providing excellent film, or other type of coating, particularly those that meet certain molecular weight and thus viscosity requirements.

[0020]The present invention relates to an edible tablet (or bead or microsphere) coating composition comprising a safe and effective amount of at least a modified CMC material, optionally, a further amount of another polysaccharide or biogum material, optionally, a safe and effective amount of a plasticizing agent, and optionally, a safe and effective amount of an ingredient, including, as examples, a flavoring agent, a pharmaceutical agent, an oral care additive, an anti-inflammatory agent, an antimicrobial agent, a surfactant, a sweetener, a vitamin, pigments, colorants, and the like. The coatings of this invention may be utilized as protectants for such active ingredients through reliable long-term coating during storage and prior to ingestion by a user. Furthermore, upon introduction within the oral cavity of a user and/or patient, the coating will delay dissolution for a sufficient time to ensure no appreciable taste change due to exposure to the surface of the target tablet (if the tablet is completely coated with the inventive coating) for effective delivery of actives occurring within the user's and/or patient's stomach/gastro-intestinal system.

[0021]All percentages and ratios used hereinafter are by weight of total composition, unless otherwise indicated. As used herein, percentage by weight of the film composition means percent by weight of the wet film composition, unless otherwise indicated.

[0022]All U.S. patents cited herein are hereby incorporated in their entirety by reference.

[0023]The edible tablet coating compositions of the present invention comprise at least one molecular weight-modified CMC material. Although such degradation may be accomplished through any type of well known method, such as acid, radiation, oxidation and heat degradation, preferably the degradation step is provided through enzymatic exposure. Thus, the initial method step is actually providing the CMC material for further use thereof. Such a step may be accomplished similarly to that taught within either of the Timonen et al. patents discussed above. In essence, a CMC having the desired degree of substitution and initial molecular weight is subjected to a preselected amount of cellulase enzyme in order to reduce the overall molecular weight of the CMC material itself to a level proper for coating production. The CMC selected for this step, as alluded to above, must exhibit a proper degree of substitution (i.e., the average amount of carboxymethyl groups per glucose unit) in order to permit the ultimate generation of a tablet coating exhibiting the requisite characteristics of active protection, delayed dissolution, dimensional stability, and low tackiness, at least. For ingestion as tablet coatings, the degree of substitution is preferably, though not necessarily, lower than about 0.95, at most as high as about 1.5. The initial molecular weight may be within a broad range as long as the ultimate molecular weight range meets the requirements that lead to the same type of proper tablet coating generation in terms of the physical characteristics noted above. Thus, an initial molecular weight range, as measured by using GPC analysis of from 80,000 to about 3,000,000 is acceptable. The thus preselected CMC starting material can then be exposed to an amount of cellulase that coincides, in combination with the amount of time of such exposure, pH and temperature with the ultimate degradation of the CMC material into individual strands thereof exhibiting a range of molecular weights from 1,500 to 75,000. If the molecular weight is too low (below 1,500), then the coating will be too friable to properly function. Preferably, though not necessarily, the molecular weight will be between about 20,000 and 50,000 for the modified CMC materials. A lower molecular weight range (i.e., from 1,500 to about 20,000) may be utilized as well, but will preferably, though, again, not necessarily, be compensated for with a higher degree of substitution. After the time of enzyme exposure is completed, the cellulase can then be inactivated through heat exposure, as one example, thereby preventing further degradation of the CMC from occurring. The molecular weight range sought after for the modified CMC materials transfers to a viscosity measurement for the solutions used to ultimately produce the target coatings typically within a range of 150 mPas to 450 mPas. It has been found as well that such viscosity measurements appear to contribute to the overall effectiveness of the ultimately formed coatings in combination with the degree of substitution of the starting CMC materials themselves. Thus, it has been determined that such molecular weight and viscosity properties are critical to the success of the overall invention, at least when the sole coating-forming component of the solution is the modified CMC material.

[0024]As noted previously, one surprising result of this invention is that the modified CMC can be utilized as such a sole coating-forming component. Most commercially available films require the utilization of combinations of different polymers to attain desired film properties; however, it has surprisingly been determined that the modified CMC polymers utilized within this invention are sufficient on their own to achieve such results. The ability to form a tablet coating that meets or exceeds the aforementioned physical characteristics as well as can withstand certain salt and relative humidity exposures without appreciably effecting the dimensional stability and usefulness of the ultimate end use product was unexpected. If desired, however, one may include other hydrocolloids, biogums, and/or cellulose ethers to provide increases in salt and/or humidity protection, or to provide viscosity build within pre-applied tablet coating formulations, or to provide gel formation for the same types of formulations, and/or one may include a plasticizer in order to increase film flexibility or provide increases in dimensional stability and other physical characteristics of the subject tablet coatings as well. Such a molecular weight-modified CMC polymer exhibits excellent compatibility with such other possible polymers and thus their optional presence should not be problematic.

[0025]The other types of optional polymeric additives that may be utilized within the inventive tablet coatings, again, in addition to the required modified CMC materials, include, without limitation, non-gelling viscosity building additives selected from the group consisting of cellulose ethers, such as methyl cellulose, (non-modified) carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and mixtures thereof; biogums, such as xanthan gum, diutan gum, rhamsan gum and welan gum, gellan gum, and mixtures thereof; and hydrocolloids such as carrageenan, pectin, gum arabic, guar, locust bean gum, gum tragacanth, tara gum, sodium alginate, acacia gum, pullulan, scleroglucan, and mixtures thereof; and any combinations or mixtures thereof such different types of hydrocolloids. Furthermore, other additives that impart gel-forming characteristics to the modified CMC formulations include, without limitation, gel-forming additives selected from the group consisting of of gellan gum (high and low acyl forms), carrageenan (kappa and iota types), xanthan/locust bean gum, sodium alginate, curdlan, MHPC, pectin, and any combinations or mixtures thereof. The optional polymeric additives listed above may be present therein in an amount of from 0.05 to 50% by weight of the entire coating.

[0026]In order to obtain a controlled release formulation, it is usually necessary to overcoat the substrate comprising the therapeutically active agent with a sufficient amount of the aqueous solution of the specific carboxymethylcellulose (as defined above) to obtain a weight gain level from about 5 to about 15 percent, although the coating may be lesser or greater depending upon the physical properties of the therapeutically active agent and the desired release rate, the inclusion of plasticizer in the aqueous solution of modified carboxymethylcellulose and the manner of incorporation of the same, for example.

[0027]One benefit of utilizing the modified CMC, particularly, whether alone or in combination with these other types of hydrocolloids and/or biogums, is the reduced viscosity exhibited thereby permits greater amounts of the modified CMC to be introduced within the initial film-forming solution (prior to coating) than is customary. As discussed above, this permits a reduction in the amount of water needed for a proper film-forming composition to be produced and drastically reduces the time required for water evaporation. Furthermore, the film-forming solution can be easily and thoroughly mixed under relatively low energy levels such that a properly dispersed solution is accorded the film producer as well. The modified CMC materials are present as long strands, rather than as coiled globules of CMC; thus, the avoidance of detrimental lumps within the film-forming solution is possible at the aforementioned low energy mixing levels. The proper coating-forming solutions thus will comprise from about 10 to about 50% of the modified CMC, from about 50 to about 90% by weight of water, and optionally, from 0 to about 12.5% by weight of a plasticizer.

[0028]In addition to the above essential modified CMC coating agents, the coating solution may also comprise other additional film-forming agents other than the hydrocolloids, cellulose ethers, and/or biogums listed above, such as, without limitation, polyvinyl pyrrolidone, polyvinyl alcohol, sodium alginate, polyethylene glycol, polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl polymer, starch, amylose, high amylose starch, hydroxypropylated high amylose starch, dextran, chitin, chitosan, levan, elsinan, collagen, gelatin, zein, gluten, soy protein isolate, whey protein isolate, casein, and mixtures thereof.

[0029]It is preferred that the aqueous solution of modified carboxymethylcellulose used in the present invention include an effective amount of a suitable plasticizing agent, as it has been found that the use of a plasticizer will further improve the physical properties of the film. The suitability of a plasticizer depends on its affinity or solvating power for the polymer and its effectiveness at interfering with polymer-polymer attachments as well as the ability of the plasticizer to act as a "swelling agent" for the CMC in the desired solvent (preferably, though not necessarily, water). Such activity imparts the desired flexibility by relieving molecular rigidity and permitting the CMC to form around the desired target substrate. Generally, the amount of plasticizer included in a coating solution is based on the concentration of the film-former, e.g., most often from about 1 to about 50 percent by weight of the film-former. Concentration of the plasticizer, however, can only be properly determined after careful experimentation with the particular coating solution and method of application. As an aqueous system is preferred, water soluble plasticizers should be utilized in this respect. Thus, preferred plasticizers include polyethyleneglycol, glycerol, and propyleneglycol. Nonaqueous systems may also be utilized. In such an instance, then, the plasticizer should be soluble within such solvents as well.

[0030]When the controlled-release coating of the present invention is to be applied to tablets, the tablet core (e.g. the substrate) may comprise the active agent along with any pharmaceutically accepted inert pharmaceutical filler (diluent) material, including but not limited to sucrose, dextrose, lactose, microcrystalline cellulose, xylitol, fructose, sorbitol, dicalcium phosphate, mixtures thereof and the like. Also, an effective amount of any generally accepted pharmaceutical lubricant, including the calcium or magnesium fatty acids may be added to the above-mentioned ingredients of the excipient prior to compression of the tablet core ingredients. Most preferred is magnesium stearate in an amount of about 0.5-3% by weight of the solid dosage form.

[0031]The coated tablet formulations of the present invention slowly release the therapeutically active agent, e.g., when ingested and exposed to gastric fluids, and then to intestinal fluids. The controlled release profile of the formulations of the invention can be altered, for example, by varying the amount of overcoating with the aqueous solution of modified carboxymethylcellulose, by varying the amount and type of plasticizer relative to modified carboxymethylcellulose, by the inclusion of additional ingredients or excipients, by altering the method of manufacture, and other techniques.

[0032]The coating solutions of the present invention preferably contain, in addition to the film-former, plasticizer, and solvent system (i.e., water), a colorant to provide elegance and product distinction. Color may be added to the aqueous solution of modified carboxymethylcellulose (CMC). For example, color may be added to the modified CMC via the use of alcohol or propylene glycol based color dispersions, milled aluminum lakes and opacifiers such as titanium dioxide, as mere examples. Any suitable method of providing color to the formulations of the present invention may be used.

[0033]The plasticized aqueous solutions of modified carboxymethylcellulose may be applied onto the substrate comprising the therapeutically active agent by spraying using any suitable coating equipment known in the art. A sufficient amount of the aqueous solution of modified carboxymethylcellulose to obtain a predetermined controlled release of said therapeutically active agent when said coated substrate is exposed to aqueous solutions, e.g. gastric fluid, is preferably applied, taking into account the physically characteristics of the therapeutically active agent, the manner of incorporation of the plasticizer, etc. After coating with modified CMC, a further overcoat of a film-former, may optionally applied to the target tablet (or microspheres, beads, and the like). This overcoat is provided, if at all, in order to substantially reduce tackiness and possible agglomeration of the tablets (or microspheres, beads, and the like), although the modified CMC should not exhibit such tacky characteristics.

[0034]Next, the coated beads are cured in order to obtain a stabilized release rate of the therapeutically active agent. Curing is traditionally carried out, if at all, via a forced-air oven at 60° C. for anywhere from 2-24 hours or in-line.

[0035]The compositions of the present invention may also comprise a safe and effective amount of an additive selected from the group consisting of a flavoring agent, an antimicrobial agent, a surfactant, a sweetener, and any combinations thereof.

[0036]Suitable flavoring agents include any well known food flavoring (of which there are a vast variety to choose from) including, without limitation, examples such as oil of wintergreen, oil of peppermint, oil of spearmint, clove bud oil, menthol, eucalyptol, lemon, orange, cinnamon, vanillin, and the like, and mixtures thereof. In another embodiment, in order to stabilize the flavor, the compositions may optionally comprise a vegetable oil.

[0037]Antimicrobial agents (preservatives) may also by optionally present in the present compositions. Such agents may include, but are not limited to alcohols, propylparaben, and methylparaben. Suitable surfactants are those which are reasonably stable and include nonionic, anionic, amphoteric, cationic, zwitterionic, and mixtures thereof.

[0038]The present compositions may optionally comprise sweetening agents including sucralose, sucrose, glucose, saccharin, dextrose, levulose, lactose, mannitol, sorbitol, fructose, maltose, xylitol, saccharin salts, thaumatin, aspartame, D-tryptophan, dihydrochalcones, acesulfame and cyclamate salts, especially sodium cyclamate and sodium saccharin, and mixtures thereof.

Preferred Embodiments of the Invention

[0039]The coating compositions utilized in accordance with the invention are formed by processes conventional in the tablet coating art. Generally, the separate components of the coating solutions are blended in a mixing tank until a homogeneous mixture is achieved. Thereafter, the coating solutions can be applied onto an appropriate tablet substrate by spraying, fluid bed drying and other coating techniques known in the tablet coating art, to an acceptable thickness. The coated tablets are then dried (cured), e.g. in a forced-air oven or in-line. The temperature of the drying air and length of drying time depend on the nature of the solvent utilized as is recognized in the art. Most of the coatings contemplated herein, however, are dried at a temperature between about 25° C. (i.e., ambient temperature) and 140° C. (with a lower temperature preferred to reduce costs), for a duration of about 20 minutes to about 60 minutes, in another embodiment from about 30 to about 40 minutes. Drying of these coated tablets should be carried out in a way that the actives included therein are not deleteriously affected by exposure to the necessary level of heat. When dried properly, the coatings will be non-tacky and will have a final water activity of 0.5 (±0.25) so that they do not either take up or lose significant amount of water when exposed to normal ambient conditions. The moisture content will vary depending upon the composition of the coating, its water activity rather than water content that is the parameter to be controlled. Coatings with a low water content may be dried in as little as 30 minutes at 40° C. The optimal temperature of the film during drying is usually lower than 65 C°. Higher temperatures can be used, especially if the film is dried simultaneously from the top and bottom.

[0040]Extrusion is also a possible method of coating solution manufacture. The mechanical particulars of the extrusion process, e.g. the particular equipment utilized, the extruding force, the shape and temperature of the orifice are considered to be within the skill of the art and can be varied in a known manner to achieve the physical characteristics of the films described herein.

[0041]The coatings herein are generally between about 0.1 and about 10 mils (about 0.025 mm to about 0.25 mm), in another embodiment from about 0.2 to about adjust this one 2.5 mils (about 0.03 mm to about 0.100 mm) thick, and will effectively provide a uniform coating over a target tablet upon application thereon. A uniform application on the surface of a target tablet should be achieved therewith. In particular, the coatings should be applied at an overall weight increase of at most 8% of the weight of the target substrate, and at least 0.5%. Outside of this range would create too great a weight increase without any increase in protective characteristics or an insufficient level of protection to the target substrate. Preferably, the amount of coating is added at a weight increase of from about 1 to 5% by weight of the target substrate, most preferably from 1.5 to 3.5%.

[0042]The processes followed for production of the inventive modified CMC materials and tablet coatings made therefrom are delineated below.

EXAMPLES

1) Modified CMC Production

[0043]Samples of different CMC materials were modified to different levels of molecular weights in order to provide materials for ultimate film coating production. In each instance, the basic degradation method was preferably performed enzymatically and followed the basic steps of: Tap water was charged to a barrel that was placed in a water bath of 50° C. From a food grade cellulase (Econase CE from AB enzymes) from Trichoderma reesei, 0.1-1% (weight percent on dry CMC basis) was added to the water (exhibiting a pH of 5.8 as adjusted by a 21% phosphoric acid solution). While stirring thoroughly CMC from CPKelco (the different types are noted within Table 1, below) was slowly added over a period of an hour to a concentration of 20% in water. The pH was then adjusted again to 5.8 using the same phosphoric acid solution. The reaction was performed at 50° C. while stirring for 16 hours and was eventually stopped by inactivating the enzyme in an autoclave at 121° C. for one hour. The resultant modified CMC solutions were then dried by either freeze-drying or spray drying.

Wednesday, January 26, 2011

filgrastim (Injection route)

Uses For filgrastim

Filgrastim is a synthetic (man-made) version of a substance that is naturally produced in your body called a colony stimulating factor. It helps the bone marrow to make new white blood cells.
When certain cancer medicines are used to fight cancer cells, they also affect the white blood cells that fight infections. Filgrastim is used to prevent or reduce the risk of infection while you are being treated with cancer medicines. filgrastim is also used to help the bone marrow recover after a bone marrow transplantation, and for a process called peripheral blood progenitor cell collection in cancer patients.
filgrastim is available only with your doctor's prescription.

Before Using filgrastim

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For filgrastim, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to filgrastim or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of filgrastim in children. However, safety and efficacy have not been established in patients with autoimmune neutropenia and babies younger than 1 month of age.

Geriatric

Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of filgrastim in the elderly. .

Pregnancy


Pregnancy Category Explanation
All Trimesters C Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking filgrastim, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using filgrastim with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
  • Topotecan
  • Vincristine
  • Vincristine Liposome

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Other Medical Problems

The presence of other medical problems may affect the use of filgrastim. Make sure you tell your doctor if you have any other medical problems, especially:
  • Bleeding problems or
  • Lung disease or breathing problems or
  • Sickle cell disease (red blood cell disease) or
  • Skin disorders (e.g., cutaneous vasculitis)—Use with caution. May make these conditions worse.
  • Bone marrow problems (e.g., chronic myeloid leukemia [CML], myelodysplastic syndrome [MDS])—It is not known if filgrastim will work in patients with these conditions.
  • Peripheral blood progenitor cell (PBPC) mobilization—Use of filgrastim is not recommended for PBPC mobilization in healthy donors.

High fructose Corn Syrup

High fructose Corn Syrup
The recent release in the US of adverts sponsored by the corn industry to promote high fructose corn syrup as being ‘not that bad’ has sparked much discussion about the ethics of marketing unhealthy products to the public.
These adverts were deeply misleading and obviously designed to capitalise upon the ignorance of consumers. Yet to anyone who knows the facts they were so wide of the mark they could almost have been a joke. When I watched them I nearly spat my breakfast onto the laptop.
This is, of course, nothing new, although the weasel tactics employed here do mark a new milestone in treating the consumer with contempt. Big business has been lobbying for, and marketing products which are patently bad for us for years. Slick advertising and well-groomed, plausible front-men have become the modus operandi for companies peddling ostensibly unacceptable products to somehow acquire for them a veneer of acceptability.
Big Business
The sugar lobby are amongst the worst offenders. When you see the roll-call of garbage-peddlers who were in league with the Sugar Association as they tried in 2003 to strong-arm the World Health Organization into withdrawing healthy eating guidelines, it’s not hard to see their angle. The story was reported in guardian.co.UK in April 2003, entitled ‘Sugar industry threatens to scupper WHO.’
The tobacco industry, after all these years, still wheel out wheezing spokespeople in times of crisis to advocate ‘freedom of choice’. One can’t help feeling as if these self-confessed smokers and advocates of choice are in some way being exploited, in spite of their clear complicity.
Pharmaceutical companies are the toughest bunch of all because their products are ostensibly acceptable. Perhaps this is how they managed to ease themselves into a position of almost unassailable power. For so long everyone just assumed they were the good guys – we took our eye of the ball. Now, when find that they are funding lavish trips for doctors to acquire influence (guardian.co.UK/society/2008/aug/23/health.pharmaceuticals), we have become aware of their true might.
The bigger the business, the greater the power and the slicker the machine. Provided someone in a well-cut suit with a good haircut can keep a straight face whilst saying advocating moderation and groundlessly refuting compelling and damning evidence then somehow, by sleight of hand and sheer chutzpah they get away with it. We are hypnotised by the gibberish, mesmerised by the gloss.

Not Fundamentally Evil

Naturally, it is tempting to brand these people and the companies they work for as bad, or even evil; but the uncomfortable truth is that these people are probably no more or less evil than you or me. They are just doing their job and too lazy, broke or ignorant to confront the fact that their job indirectly causes suffering.
In my line of work I am indirectly involved in the promotion of some of the products I rail against in this blog. Shame on me, you might say. Why don’t I quit my job and get new job planting trees? Money. Security. Ambition. Hypocrisy, perhaps. But I promise I am not a bad person.
Likewise, the companies cannot, by definition, be evil. They are simply a collection of people, policies and processes that have evolved under the system we know as capitalism. The company is owned by the shareholders but run by the employees. The shareholders want the company to continue making profits because this pays their bills. To keep the shareholders happy the employees must take whatever actions are most likely to keep the company making profits so that their wages continue to be paid and they can pay their own bills.
Even the shareholders are arguably no worse than the employees themselves. You could question the ethics of their investments but I am guessing that for the most part they are not bad people.

The Corporation as a Sociopath

In the film The Corporation, the way companies behave was examined in the context of psychiatry. The conclusion was that when examined in these terms, companies exhibit the traits of a sociopath. In other words, someone
…who lacks a sense of moral responsibility or social conscience
I believe this is fundamentally at the root of many of our problems with big business pushing products that are bad for us. A collection of people with no particular desire to harm others, when assembled into a group under the corporate system, end up conspiring to do so. The sum of the parts is greater than the whole.
The majority of the time, this is not a problem. Most companies are making products that people want to buy. We have regulations that ensure those products meet certain standards and laws to enforce those regulations; and even in the worst companies (such as tobacco manufacturers) there will be a presumption to favour the consumer’s wellbeing when there is more than one choice but no effect on profit.

Painting themselves into a Corner

The problem comes when two circumstances align.
First, product development accelerates faster than research and regulation. HFCS is a good example – if we had known about its effects when it was first being introduced into foods, would it have got this far? Banning something on which few profits depend is easy because there are no lobbies. Maybe the research was there but the regulators we slow. Either way, the problem is that very often, the organizations developing the products have more money to spend than the researchers and regulators.
Second – and this is the key one – a company gets itself into a position where its financial well being depends on continuing to sell a product that turns out to be bad. It paints itself into a corner.
In the case of tobacco companies, there really was nowhere for it them go with their products when it started to become clear that tobacco was a killer. Even if the CEO stood up at the board meeting and said I think we should fold the company because we sell poison, the board would oust him; and even if the board agreed with him, they could not get it past the shareholders, who, after all, own the company; and the shareholders are not going to throw away their investment. If they were that way inclined, their money would be invested elsewhere.
The corn industry, at some point, decided that HFCS was the way forward. They invested in infrastructure and supply chains and developed a healthy customer base. They got themselves to the point where a lot of their revenue depended on HFCS and for them it’s a no-brainer: they must find a way to preserve that revenue stream using whatever means necessary. When someone’s back is against the wall, they act unreasonably – this appears to apply to sociopaths too.

Are we Doomed?

Don’t get me wrong – there are some bad people out there. I have made some assumptions and simplifications to allow me to develop my point. Clearly there have been and continue to be individuals in companies who themselves behave psychopathic ally and could reasonably be called bad; but stick with me here – what I am saying is that for the most part this is not the case. For the most part, people are just doing what they must to live their life. They have constructed a view of the world to allow them to live their lives without daily fretting.
Nothing is easier than self-deceit. For what each man wishes, that he also believes to be true.
~Demosthenes, prominent Greek statesman and orator of ancient Athens.
So are we doomed? I don’t believe so. The good news – or at least the best news we can hope to get under the circumstances is that the amorality of companies presents as much of an opportunity as it does a threat. They are, for the most part, interested in just a couple of things – self-preservation and profit.
Companies usually come into being when someone decides they can make money from selling something. It’s unlikely any of the companies that began refining sugar in the 18th and 19th centuries in England had any idea their product would become the scourge of the western diet. If they had seen similar opportunities in the penicillin market no doubt they would have been equally inclined to make that (although of course it would not be discovered until the 20th century.)

Companies Follow the Dollar

If the bigwigs at British American tobacco discover that that tobacco, when treated in a certain way produced the most alluring, harmless aromatic scent that consumers were just crazy about and would pay twice as much for, you can bet they’d have their business realigned accordingly within months. In the context of a burgeoning market for potpourri, you can also bet their cigarette manufacturing arm, with its attendant legal and regulatory burdens, would quietly dwindle to nothing within a decade. Companies follow the dollar, pure and simple.
McDonalds, that arch-villain of the food world, bought Pret a Manger in 2001. Now I’m not saying Pret a Manger sells healthy food – a recent UK TV program about sandwiches disabused me of any such notion – but next to McDonald’s own food, Pret’s is a shining beacon of nutritional excellence. The point being, McDonald is getting a whiff of the coffee and investing strategically. They sense a shift towards the healthy option and are getting ready to move with the times. They are not passionate about selling burgers – they sell them because right now that’s where the money’s at.
Have you ever watched a game of soccer being played by young kids? They scuttle around the pitch in a group, following the ball wherever it goes. For grown-up aficionados of the game this is an amusing spectacle, but for the kids, who at this age have largely their own self-interest in mind (they just want to kick the ball), it makes perfect sense. Companies follow the dollar like these kids follow the soccer ball; and since it’s our dollars they are chasing, that makes us – the consumers – the ball.
In such games, the referee’s job is to make sure the players behave themselves during the scramble for the ball; but since young children have not yet grasped the concepts of fair play and rules, this is not an easy task. If the teacher is one of those well-intentioned but bumbling types, easily manipulated by the kids’ pleas, then the game can degenerate, with the rules being followed only in the loosest sense. The regulators and lawmakers, particularly those responsible for nutritional regulation, are this kind of referee.
Balance of Power in Our Favour
So let’s examine the balance of power between big business and the little man. There are three key ways that companies are able to exert influence:
Marketing. As we have seen from the HFCS adverts, companies can employ slick techniques to convince consumers they should buy products.
PR. Companies routinely use the media to their advantage by releasing stories to show their products in a positive light.
Lobbying. Vast sums of money are spent on legal and professional services with which companies put pressure on the regulators to make decisions favourable to their interests.
On the other hand, there are four key groups who can influence companies:
Consumers. If we don’t buy the product, companies will not make money out of it and will look for other things to sell.
Shareholders. Each year, they take part in a meeting at which they can table motions that affect company policy and lobby other shareholders to vote on them.
The Media. It has the power to publicly bring companies to account for misdeeds and educate the public about products.
The Regulators. I include in this category the lawmakers and government. They can remove products entirely from circulation or make life difficult for companies to make money from them, for example through taxation or stringent regulations.
On the face of it, companies are at a disadvantage – they are being influenced from all directions and have comparatively fewer ways to exert their own influence. More importantly, if you examine the ways they can be influenced, the consumer has the power to act either directly or indirectly in all cases.
Companies throw billions at the means influence they do have – lobbying, marketing and PR. They would regard these activities as pivotal to their success. If as much effort was devoted to the ways we can influence companies, the balance of power would begin to shift to the little man. In this battle, effort equates to money and although the companies have a lot of money which buys a lot of effort, even the vast coffers of entire industries could not buy enough effort if every consumer exerted their potential influence in the same direction.
Buying Power
If consumers buy less of a product, companies make less money out of it and focus their attention elsewhere. Many of us make compromises for the sake of convenience or cost so we all have an opportunity to influence in a small way. It may not feel like it makes any difference if we stop buying that once-a-week trail-mix bar because it has some kind of corn syrup in – but it does. The company manufacturing those bars will be watching sales like a hawk. If sales drop even a little, they run focus groups. In those groups, someone like you will tell them why they stopped buying the bars.
We are the Media
There was a time when the little man would sit at his desk writing letters to newspapers complaining about the world. They would rarely be published or used as the basis for a story.
With the advent of the Internet, particularly what has been dubbed ‘web 2.0′, this has profoundly changed. Now you can contact the media and companies much more easily and free of charge. Just find the website, write an email and boom, you’ve scored a point for the little man. Many news websites allow you to comment on stories now – so there is even a guarantee that your views will be published.
And that’s the point – now we are the media. The fact that you are reading this blog proves that; and you don’t have to be a blogger to make your views known – the participatory web has generated a wealth of opportunity for the little man to seize control from companies. Don’t like the corn industry’s adverts? Create a spoof and post it on You Tube. If you make it funny enough it might even get more views that the originals. In fact by way of example, I have gone ahead and done just that, there is a link at the bottom.
Companies are scared of the pace at which technology and the socialization of media is changing. They have accepted that they will, for the foreseeable future, be one step behind the consumer in this medium – it’s up to us to take advantage of that.

Contact the Regulators 

Just as it has become easy to contact companies and the media thanks to the Internet, likewise the regulators are suddenly within easy reach. Formerly these bodies were remote and almost mythical, mentioned in the news but never seen anywhere else. Now they have websites and can be found in search engines or linked to on blogs and other sites. In many cases, regulators welcome comments and complaints from the public and will act on the consumer’s behalf in disputes.
Even politely acknowledged emails sent to governments make an impact – someone has to read these emails and someone else takes note of the numbers of emails about a certain topic. Someone else then looks at these numbers and decides what issues matter to the public so they can advise politicians on what to talk about in speeches or propose as legislation.
Clearly the regulators and lawmakers read and are affected by the media, so the little man’s influence can come from more than one direction for the regulators.

Become a Shareholder…or Don’t

The public ownership of companies may be at the root of company psychopathy, but it nevertheless represents an opportunity for the little man to influence company behavior in more ways than one.
First, by ethical investment. Share value is important to companies and influences their power. If investors go out of their way to avoid funds, banks and other financial instruments or bodies that are known to invest in companies they disapprove of, they make a difference. There are a growing number of ethical funds and financial institutions out there and although there may not yet be any who avoid investing in the corn industry, they are certainly addressing issues like tobacco and fair trade.
Alternatively, become a shareholder activist. In May 2008 UK TV Chef Hugh Fearnley-Whittingstall bought a stake in UK supermarket behemoth, Tesco and tabled a motion for the June meeting of shareholders, calling for changes to animal welfare. He persuaded the holders of £3m worth of shares to vote in his favour, but unfortunately lost. Nevertheless, this shows what can be done with shareholder power and of course even though he lost, he scored a big win via the media coverage. (Hugh Fearless-Whittingstall calls on Tesco shareholders to protest over cheap chickens.)
Corporate Social Responsibility
The existence of corporate social responsibility (CSR) bears witness to the influence we can have over companies. If companies are interested in the dollar and self-preservation then CSR proves that companies realise that our opinion has the ability to make or break them. Now companies are falling over themselves to prove how ethical they are. If you search in Google for CSR plus the name of a major company you will invariably find well-crafted policies, open forums or other web sites designed to show that the company cares. Even British American Tobacco has found a way to contrive a veneer of caring.
Psychopaths will often feign emotions they are not capable of having in order to achieve their objectives; but from the little man’s perspective it matters not how genuine the sentiment is when companies flash us their best smile – what matters is that they are doing it.
I’ll end with a quote from Adam Smith, Scottish moral philosopher and a pioneer of political economy:
Consumption is the sole end and purpose of all production; and the interest of the producer ought to be attended to, only so far as it may be necessary for promoting that of the consumer.

Prelone Syrup

Prelone Syrup is used for:

Rheumatoid Arthritis Learn the signs of RA and how to relieve the pain.
Treating allergies, arthritis, breathing problems (eg, asthma), certain blood disorders, collagen diseases (eg, lupus), certain eye diseases (eg, keratitis), cancer (eg, leukemia), endocrine problems (eg, adrenocortical insufficiency), intestinal problems (eg, ulcerative colitis), swelling due to certain conditions, or skin conditions (eg, psoriasis). It may also be used for other conditions as determined by your doctor.
Prelone Syrup is a corticosteroid. It works by modifying the body's immune response to various conditions and decreasing inflammation.

Do NOT use Prelone Syrup if:

  • you are allergic to any ingredient in Prelone Syrup
  • you have a systemic fungal infection, a certain type of malaria, inflammation of the optic nerve, or herpes infection of the eye
  • you are scheduled to have a live or attenuated live vaccination (eg, smallpox)
  • you are taking mifepristone
Contact your doctor or health care provider right away if any of these apply to you.

Before using Prelone Syrup:

Some medical conditions may interact with Prelone Syrup. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
  • if you are pregnant, planning to become pregnant, or are breast-feeding
  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement
  • if you have allergies to medicines, foods, or other substances
  • if you have a history of heart problems (eg, congestive heart failure), heart attack, high blood pressure, kidney problems, liver problems, diabetes, seizures, an underactive thyroid, adrenal gland problems, or any mental or mood problems
  • if you currently have or have recently had a fungal, bacterial, viral, or other type of infection; herpes infection of the eye; chickenpox; measles; or shingles
  • if you have HIV infection, tuberculosis (TB) infection, or if you have had ever had a positive TB skin test
  • if you have any stomach problems (eg, ulcers), intestinal problems (eg, blockage, perforation, or infection; unexplained diarrhea; diverticulitis; ulcerative colitis), recent intestinal surgery, or inflammation of the esophagus
  • if you have weak bones (eg, osteoporosis) or muscle problems (eg, myasthenia gravis)
  • if you have had a recent vaccination (eg, smallpox)
Some MEDICINES MAY INTERACT with Prelone Syrup. Tell your health care provider if you are taking any other medicines, especially any of the following:
  • Barbiturates (eg, phenobarbital), carbamazepine, ephedrine, hydantoins (eg, phenytoin), or rifampin because they may decrease Prelone Syrup's effectiveness
  • Clarithromycin, cyclosporine, estrogens (eg, estradiol), oral contraceptives (eg, birth control pills), or ketoconazole because they may increase the risk of Prelone Syrup's side effects
  • Anticholinesterases (eg, pyridostigmine), aspirin, methotrexate, mifepristone, ritodrine, water pills (eg, hydrochlorothiazide, furosemide), or live or attenuated live vaccines because the risk of their side effects may be increased by Prelone Syrup
  • Anticoagulants (eg, warfarin) or killed or inactivated vaccines because their effectiveness may be decreased by Prelone Syrup
This may not be a complete list of all interactions that may occur. Ask your health care provider if Prelone Syrup may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
How to use Prelone Syrup: Use Prelone Syrup as directed by your doctor. Check the label on the medicine for exact dosing instructions.
  • Take Prelone Syrup by mouth with food.
  • Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
  • If you miss a dose of Prelone Syrup, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Prelone Syrup.

Important safety information:

  • Prelone Syrup may lower the ability of your body to fight infection. Avoid contact with people who have colds or infections. Tell your doctor if you notice signs of infection like fever, sore throat, rash, or chills.
  • If you have not had chickenpox, shingles, or measles, avoid contact with anyone who does.
  • If you are taking Prelone Syrup regularly over a long period of time, carry an ID card at all times that says you take Prelone Syrup.
  • Do not receive a live vaccine (eg, measles, mumps) while you are taking Prelone Syrup. Talk with your doctor before you receive any vaccine.
  • Tell your doctor or dentist that you take Prelone Syrup before you receive any medical or dental care, emergency care, or surgery.
  • Diabetes patients - Prelone Syrup may affect your blood sugar. Check blood sugar levels closely. Ask your doctor before you change the dose of your diabetes medicine.
  • Lab tests, including adrenal function tests, may be performed while you use Prelone Syrup. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.
  • Caution is advised when using Prelone Syrup in CHILDREN; they may be more sensitive to its effects.
  • Corticosteroids may affect growth rate in CHILDREN and teenagers in some cases. They may need regular growth checks while they take Prelone Syrup.
  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Prelone Syrup while you are pregnant. Prelone Syrup is found in breast milk. If you are or will be breast-feeding while you use Prelone Syrup, check with your doctor. Discuss any possible risks to your baby.
If you are on long-term or high dosage therapy and you suddenly stop taking Prelone Syrup, you may have WITHDRAWAL symptoms, including fever, vomiting, appetite loss, diarrhea, nausea, dizziness, weight loss, weakness, general body discomfort, joint or muscle pain.

Possible side effects of Prelone Syrup:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Acne; clumsiness; dizziness; facial flushing; feeling of a whirling motion; general body discomfort; headache; increased appetite; increased sweating; nausea; nervousness; sleeplessness; upset stomach.
          Seek medical attention right away if any of these SEVERE side effects occur:
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); black, tarry stools; changes in body fat; changes in menstrual period; changes in skin color; chest pain; easy bruising or bleeding; infection (eg, fever, chills, sore throat); mental or mood changes (eg, depression); muscle pain, weakness, or wasting; seizures; severe nausea or vomiting; sudden severe dizziness or headache; swelling of feet or legs; tendon or bone pain; thinning of skin; unusual skin sensation; unusual weight gain; vision changes or other eye problems; vomit that looks like coffee grounds.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the .


If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Proper storage of Prelone Syrup: Store Prelone Syrup at room temperature, between 59 and 86 degrees F (15 and 30 degrees C), in a tightly closed container. Store away from heat, moisture, and light. Do not refrigerate. Do not store in the bathroom. Keep Prelone Syrup out of the reach of children and away from pets.

General information:

  • If you have any questions about Prelone Syrup, please talk with your doctor, pharmacist, or other health care provider.
  • Prelone Syrup is to be used only by the patient for whom it is prescribed. Do not share it with other people.
  • If your symptoms do not improve or if they become worse, check with your doctor.
  • Check with your pharmacist about how to dispose of unused medicine.
This information is a summary only. It does not contain all information about Prelone Syrup. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Metoclopramide Syrup

Generic Name: Metoclopramide Syrup (meht-oh-KLOE-pra-mide)
Brand Name: Generic only. No brands available.

Metoclopramide Syrup is used for:

Short term treatment of gastroesophageal reflux disease (GERD) in certain patients who do not respond to other therapy. It is used to treat symptoms of a certain digestive problem in diabetic patients (diabetic gastroparesis). It may also be used for other conditions as determined by your doctor.
Metoclopramide Syrup is a gastrointestinal stimulant and anti-nauseant. It works by increasing the movement of the stomach and intestines to help move food and acid out of the stomach more quickly. It also works in certain areas in the brain to decrease nausea.

Do NOT use Metoclopramide Syrup if:

  • you are allergic to any of the ingredients contained in Metoclopramide Syrup
  • you have seizures (eg, epilepsy); bleeding, blockage, or perforation in your stomach or intestines; or tumors on your adrenal gland (pheochromocytoma)
  • you are taking cabergoline or pergolide
  • you are taking medicines, such as phenothiazines (eg, chlorpromazine), that may cause extrapyramidal reactions (abnormal, involuntary muscle movements of the head, neck, or limbs)
Contact your health care provider as soon as possible if any of the above applies to you.

Consider before using Metoclopramide Syrup

Medical Conditions

There are medical conditions that can influence usage of Metoclopramide Syrup. Tell your doctor or pharmacist if any of the medical conditions below applies to you:
  • if you are either pregnant or planning to become pregnant
  • if you are breast-feeding
  • if you are taking any medicine (either prescription or nonprescription), herbal preparation, or dietary supplement
  • if you are allergic to medicines, foods, or other substances
  • if you have depression, asthma, heart failure, high blood pressure, diabetes, Parkinson disease, blood problems (eg, porphyria), kidney problems, or low levels of an enzyme called methemoglobin reductase

Drugs Interaction

There are medicines that may interact with Metoclopramide Syrup. Inform your health care provider if you are taking any other medicines, in particular any from the list below:
  • Cisapride or droperidol because side effects, such as muscle rigidity, increased heart rate, and altered mental abilities, may occur
  • Anticholinergic medicine (eg, hyoscyamine), certain antihistamines (eg, diphenhydramine), or narcotic pain medicines (eg, codeine) because they may decrease Metoclopramide Syrup's effectiveness
  • Acetaminophen, alcohol, levodopa, phenothiazines (eg, chlorpromazine), sedatives (eg, zolpidem), selective serotonin reuptake inhibitors (SSRIs) (eg, fluoxetine), succinylcholine, or tetracycline because the risk of their side effects may be increased by Metoclopramide Syrup
  • Monoamine oxidase inhibitors (eg, phenelzine) because the risk of serious side effects (eg, high blood pressure, seizures) may be increased
  • Cabergoline, digoxin, or pergolide because their effectiveness may be decreased by Metoclopramide Syrup
This is not a full list of all interactions that may occur. Clarify with your health care provider whether Metoclopramide Syrup may interact with other medicines you take. Also, consult your health care provider in advance if you are going to start, stop, or change the dose of any medicine.

Metoclopramide Syrup Usage Guidelines

You should use Metoclopramide Syrup as recommended by your doctor. Read the medicine's label for precise dosing instructions.
  • Take Metoclopramide Syrup by mouth 30 minutes before meals unless directed otherwise by your doctor.
  • Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
  • It may take several days to weeks for Metoclopramide Syrup to work. Do not stop using Metoclopramide Syrup without checking with your doctor.
  • If you miss a dose of Metoclopramide Syrup, take it as soon as you get it remembered. However, if it is almost time for the next dose, ignore the missed one and get back to your normal dosing schedule. Do not take 2 doses at the same time.
Clarify with your health care provider any issues you may have about usage of Metoclopramide Syrup.

Important safety information on metoclopramide

  • Metoclopramide Syrup may cause drowsiness, dizziness, or blurred vision. There effects may be worsened when this medicine is taken with aclohol or other medicines. Use Metoclopramide Syrup with caution. Refrain from driving or performing other possibly dangerous activities until you know how you react to it.
  • Do not drink alcohol or use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers) while you are using Metoclopramide Syrup without first checking with your doctor; it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.
  • Diabetes patients- Metoclopramide Syrup may affect your blood sugar. Check blood sugar levels closely. Ask your doctor before you change the dose of your diabetes medicine.
  • Neuroleptic malignant syndrome (NMS) is a possibly fatal syndrome that can be caused by Metoclopramide Syrup. Symptoms may include fever; stiff muscles; confusion; abnormal thinking; fast or irregular heartbeat; and sweating. Contact your doctor at once if you have any of these symptoms.
  • Some patients who take Metoclopramide Syrup may develop muscle movements that they cannot control. This is more likely to happen in elderly patients, especially women. The chance that this will happen or that it will become permanent is greater in those who take Metoclopramide Syrup in higher doses or for a long time. Muscle problems may also occur after short-term treatment with low doses. Tell your doctor at once if you have muscle problems with your arms; legs; or your tongue, face, mouth, or jaw (eg, tongue sticking out, puffing of cheeks, mouth puckering, chewing movements) while taking Metoclopramide Syrup.
  • Lab tests, including liver and kidney function tests, may be performed while you use Metoclopramide Syrup. These tests can be used to monitor your medical condition or to check for side effects. Be sure to keep all doctor and lab appointments.
  • Metoclopramide Syrup should not be used in CHILDREN younger than 15 years old; safety and effectiveness in these children have not been confirmed.
  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Metoclopramide Syrup while you are pregnant. Metoclopramide Syrup is found in breast milk. If you are breast-feeding or going to breast-feed, discuss with your doctor any possible risks to your baby.

Side effects may be caused by Metoclopramide Syrup

Any medicine may cause side effects, but the majority of people have either slight side effects, or dont have it at all. Consult your doctor if any of the most COMMON side effects from the list below persist or start bothering you:
Decreased energy; diarrhea; dizziness; drowsiness; headache; nausea; restlessness; tiredness; trouble sleeping.
Seek medical care immediately if any of the following SEVERE side effects occur:
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); abnormal thinking; confusion; dark urine; decreased coordination; decreased sexual ability; fast, slow, or irregular heartbeat; fever; hallucinations; loss of bladder control; mental or mood changes (eg, depression, anxiety, agitation, jitteriness); seizures; severe or persistent dizziness, headache, or trouble sleeping; severe or persistent restlessness, including inability to sit still; shortness of breath; stiff or rigid muscles; sudden increased sweating; sudden unusual weight gain; suicidal thoughts or actions; swelling of the arms, legs, or feet; uncontrolled muscle movements (eg, of the arms, legs, tongue, jaw, cheeks; twitching; tremors); vision changes; yellowing of the skin or eyes.
It sholud be noted, that this is not a full list of possible side effects. If you have questions or need medical advice about side effects, contact your doctor or health care provider. You may report side effects to the FDA at 1-800-FDA-1088 (1-800-332-1088) .

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center  or emergency room immediately. Symptoms may include agitation; confusion; drowsiness; muscle restlessness; unusual movement of eyes, face, or limbs.
Proper storage of Metoclopramide Syrup:Store Metoclopramide Syrup at room temperature, between 68 and 77 degrees F (20 and 25 degrees C) in a tightly closed container. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Metoclopramide Syrup out of the reach of children and away from pets.

General information:

  • If you have any questions on Metoclopramide Syrup, please consult your doctor, pharmacist, or health care provider.
  • Metoclopramide Syrup is supposed to be used only by the patient it is prescribed to. Do not share it with other people.
  • If your symptoms do not improve or even become worse, inform your doctor.
This article is a summary only, and it does not provide all the information about Metoclopramide Syrup. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Tuesday, January 18, 2011

injection mold manufacturing of new technologies and new trends in analysis

injection mold manufacturing of new technologies and new trends in analysis



In order to be able to produce injection molding processors can save investment costs and time costs, and
improving production efficiency injection mold, mold manufacturers increasing use of new materials and new technologies, and these new materials and new technologies in a certain extent, represent plastic injection mold manufacturing a new trend.
New material to promote the development of mold inserts
    There is a new material can reduce the injection mold manufacturer's investment cost and time cost. The new cobalt-chromium alloy, called MP1, specifically for the Rapid Prototyping (RP) device, a direct metal laser sintering (DMLS) process was developed. The material from the German rapid prototyping equipment and materials suppliers EOS (Electromagnetically) GmbH company. Now users in North America and the United States through the EOS of North America MorrisTechnologies companies to buy such material.
    MorrisTechnologies is an injection mold development company, this company the first time, the materials used in commercial manufacturing. In the company's use of the process, the cobalt-chromium alloy has been shown to have high strength, high temperature performance and corrosion resistance. MorrisTechnologies was the U.S. introduction of the first EOS's EosintM-level rapid prototyping machine company, because at that time the company had foreseen DMLS-based rapid prototyping huge market. However, experiments found that when the market still do not have a lot of material to meet their customer's application requirements.
    "There are many projects require rapid prototyping solutions, but the experimental conditions, our customers need for materials with better high temperature and corrosion resistance and higher mechanical properties." MorrisTechnologies the company's president GregMorris said, "even if it took more time and money, stainless steel or other alloys still can not meet their requirements. "
    In order to address these issues, MorrisTechnologies has selected EOS of cobalt-chromium MP1 material. Morris said that the alloy Rockwell hardness of 30 to 40 between the mold to produce a small complex products, these products are now typically used or EDM machining method to create.
    Because the structure of this material layer is very thin, only 20μm, so products can be fully sintered. Morris believed that such materials and metal laser sintering technology to help direct Injectio


n Mold Making manufacturer  industry in order to lower the cost of production of fine-type core and cavity inserts. "At present, there is no reason why a lot of mold manufacturers to adopt the technology, in my opinion, is because many people believe that they only used the old order manufacturing mold core and cavity be considered the best." Morris explained.
Clear Conservative
    Mold maker LinearMold & Engineering Inc. CEO Johnnycake not hesitate to adopt the above techniques. Because Tenbusch found that the company's EOS direct metal laser sintering rapid prototyping equipment, new customers have even extended to Mexico and South America.
    In the injection mold manufacturing process, using a typical EDM equipment (EDM) is a more popular on welding, and wire cutting in the fast-forming mold is also a gradual increase in the use. This, Tenbusch explained: "With wire cutting can help us save time, that is, we use wire cutting to cut out the cavity, while the insert such as the fine components using DMLS process to process."
    Tenbusch introduced a high accuracy of this method, but do not need to be a lot of measuring points, while rib muscle can be separated and as vents. Can also be processed using the wire cutting some stainless steel inserts, and place them in the mold. If the material hard enough and long enough life time, processing personnel will not have the details necessary to EDM parts, and as for the usual pre-hardened high-tensile steel nitrided die is the case. The use of wire cutting can be 4 to 5 weeks to complete mold manufacturing, which accelerated the root cause lies in the DMLS equipment EOS EDM equipment replaced.
    Co-Cr-MP1 is the EOS family of the company's new stainless steel 17-4 in a series, it is planned to the market this year is MaragingSteelMS1, this is a 18 martensitic steel 300 (Model: 1.2709), its performance at least equivalent to or even superior to the traditional mold steel, very suitable for fabrication using DMLS mold insert.
Less polished, multi-coated
    U.S. Bales Mold Service, Inc. is a leading injection mold to provide polishing and electroplating services. Out of consideration for the customer to reduce costs, the company is now seldom used premium EDM polishing technology, replaced by the introduction of plating technology in the mold surface coatings. Bales Mold Service Company President Steve Bales, said: "Now is not required each mold polishing, and coating use is gradually growing. We have adopted in lieu of electroplating polishing EDM live, you can save time and money for customers."
    As we all know, fillers will shorten the life of injection mold. With the injection molding of the growing amount of filler, filler to the mold caused by corrosion and wear to highlight the growing problem. The increase in coating for mold, such as Nicklon (a nickel-PTFE coating) and Nibore (nickel-boron nitride) is able to play a very good protection. At the same time with the plastic lubricant additive expensive compared to those of coating and very cheap.
    Ritemp be provided with suitable temperature with
    Australia Ritemp Corporation (Australia processing and auxiliary equipment suppliers ComtecIPE branch) in 2005 launched the Ritemp mold cooling technology. At present the technology in North America, from SWM & Associates Inc. exclusive agent.
    Using Ritemp mold cooling technology, can achieve higher cooling efficiency and shorter cycle times. Such as injection molding an electrical 15g shell, use the GEPlastics the NorylPA / PPE, for the two-cavity mold, molding cycle 18s. The use of Ritemp cooling technology you can use the four-cavity mold, and make molding cycle down to 13s, the resulting output can be more than 7 million. SWM & Associates Company believes that if the downstream equipment can handle more products, molding cycle can even be reduced to 10s.
Ritemp works as follows: Ritemp with the mold surface of the cooling water tank instead of water cannon. The vacuum created by removal of air and water to boiling temperature in the cooling room. Water evaporation to the mold surface heat exchange, and then discharged through the sink. In the evaporation process, the water molecules absorb heat and, through the mold temperature control system for regulating the heat level, thereby ensuring that the mold temperature.
    The use of submerged gate gate insert to eliminate the visible signs of
    This submerged gate inserts from Germany, i-mold company, its injection site was designed in the end products, while the flow channel from the front open, so that the surface of positioning products on the gate inconspicuous place. For example, in product outer edge of the side gate at the bottom of rib muscle, people can not see the obvious signs of the gate.

Injection Mold Making

 injection mold is a device made of metal to produce a plastic product faster, less expensive, and more consistent.

How does injection molding works?

Just heat the resin until it melts then force it into the cool mold. Allow it to solidify. Open the mold then take off the molded part.
That’s it!
As the molten resin is being injected into the mold, it enters the mold opening called the sprue. From the sprue this molten material will then be distributed to the runners then it will be fored into the gate and then into the cavity. The cavity must be filled precisely to avoid short shots but it must not be over packed (over packing is forcing more than enough pressure to the resin and it can damage the mold). The molten resin will stay in the cavity for 30 seconds to 1 minute or more until it cools down and solidify. When the resin solidify a molded part is formed. The mold will open and then the molded part will be ejected. The mold closes and its ready for another shot.

Why is an injection mold expensive?

Injection molds are made up of special, high quality steels that have a good machinability property. Some standard mold components such as springs, bolts, and limit switch are prefabricated and costs lower.

Most standard components such as ejector pins, ejector sleeves, sprue bushings, and leader components are not prefabricated which mean they will only be manufactured when you order them. They are not mass produced thus they are expensive. The cavity and core are mold components which make the mold really expensive. It involves careful design engineering and processing. Most of the tools used in making these components are very expensive.
Posted in Injection Molding | Tagged molder, molding | 

Injection Molder and Molding Machine

Injection molder or injection molding machine is a machine for producing plastic molded parts by molding process. It has 2 main parts, an injection unit and a clamping unit.
Injection molder
An injection molder have 2 methods of fastening the mold -horizontal or vertical. Most injection molder are horizontally oriented because molded parts can easily be removed after ejection by leveraging gravity -the molded parts will just fall down into the container below. Vertical injection molders are used for insert molding applications because inserts are inserted into the core side of the mold before molding.
There are also manual injection molder for hobbyists. It is simple in consruction and does require manual force to inject the resin. An example of such machine is from Galomb, Inc. They make Benchtop injection molder.

Types of injection molding machines

Injection machines are classified mainly by the type of system that drives them: Hydraulic, electric, or hybrid.
Hydraulic injection machines uses ram system for its clamping mechanism. This type of machine is used by majority of molding companies.
Electric injection machines are driven by motors. Unlike the hydraulic machines, which continously pump hydraulics to the cylinder throughout the whole molding cycle, an electric machine only makes use of energy during closing and openning of the clamping unit. It uses toggle system for its clamping mechanism in order to build up tonnage. It is also faster, quieter, and have higher accuracy, but it is also known to be more expensive. The first maker of electric injection machine is Nissei Plastic Industrial Co., LTD.
Posted in Injection Molding | Tagged machine, molder, molding | Leave a comment

Injection Molded Parts Design

Injection molded parts are made of thermoplastics, a polymer that turns into liquid when heated then turns back to solid when cooled.
Carefull thoughts on the following elements shall be considered for the design of plastic injection molded part.

Wall Thickness

As much as possible use a uniform wall thickness. If you must change the wall thickness, change it gradually to avoid warping.
If the strength is not compromised, design the part with minimal wall thickness to allow faster cooling time and cycle time.

Draft angles

Draft angle is necessary for easy removal of molded part from the mold. Draft angle should be applied in the direction of draw from the cavity and core.
Parts with textured surface require greater draft angle in order to avoid scratches on the textured surface as the part is being removed from the mold. 1 to 3 degrees normally applies to moderately matte or sand-blasted surfaces and 3 to 5 degrees for roucher surface.
But for smaller precision molded parts, it is sometime unnecessary to include draft angles as long as the cavity and core are highly polished.

Corner Radius

Apply radius on corners as much as possible. A proper radius size is not less than the wall thickness of the part.
Radius reduces the stress on the corner thus reducing the warpage compared to corners without radius.

Rib

Apply rib instead of using thicker wall thickness. Uneven cooling of thick wall will lead to uneven shrinkage inside and outside the wall. This could cause warpage and sinkmark due to internal stress. Applying rib will help improve the rigidity and geometric integrity of the molded part. It also improves the cooling time.
Posted in Part Design | Tagged molding, part design | Leave a comment

Rapid Prototyping


Rapid prototyping is a technology used to rapidly construct solid objects using three-dimensional computer aided design (CAD) data. The first technique in prototyping, stereolithography, was develop in the late 1980′s to produce prototype parts and models. In todays rapid prototyping techniques, parts can be manufactured in near production-quality in relatively small numbers, sometimes eliminating the use of injection molded parts.
Among the obvious advantages of rapid prototyping are:
  1. costly faulty designs can be reduced early in the development stage,
  2. effective communications between marketing, engineering, manufacturing, and purchasing,
  3. development time can be reduced,
  4. minimize engineering changes
These advantages greatly benefits the product development process in terms of cost, quality, and lead-time.
Rapid prototyping process:
  1. 3D CAD model is converted to Stereolithography (.STL) format.
  2. The Rapid Prototyping machine processes the STL file layer by layer.
  3. Manual finishing and cleaning.